UBS Group
TLSI icon

UBS Group’s TriSalus Life Sciences TLSI Stock Holding History

UBS Group’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Buy
79,552
+74,403
+1,445% +$364K ﹤0.01% 6369
2025
Q4 		$35.9K Sell
5,149
-3,829
-43% -$21.4K ﹤0.01% 7408
2025
Q3 		$41.7K Sell
8,978
-7,714
-46% -$36.1K ﹤0.01% 7693
2025
Q2 		$91K Buy
16,692
+9,883
+145% +$53K ﹤0.01% 7318
2025
Q1 		$37.6K Buy
6,809
+6,787
+30,850% +$36.1K ﹤0.01% 7790
2024
Q4 		$110 Hold
22
– – ﹤0.01% 9639
2024
Q3 		$101 Sell
22
-1,966
-99% -$10.4K ﹤0.01% 9159
2024
Q2 		$11K Buy
1,988
+1,597
+408% +$13.5K ﹤0.01% 7667
2024
Q1 		$3.81K Sell
391
-16,424
-98% -$152K ﹤0.01% 7695
2023
Q4 		$142K Sell
16,815
-8,117
-33% -$41.8K ﹤0.01% 5983
2023
Q3 		$128K Buy
24,932
+24,910
+113,227% +$204K ﹤0.01% 5673
2023
Q2 		$231 Sell
22
-90
-80% -$936 ﹤0.01% 8362
2023
Q1 		$1.15K Sell
112
-1,947
-95% -$19.7K ﹤0.01% 8798
2022
Q4 		$20.7K Buy
2,059
+2,037
+9,259% +$20.4K ﹤0.01% 7619
2022
Q3 		$0 Sell
22
-24,795
-100% -$245K ﹤0.01% 10924
2022
Q2 		$244K Buy
24,817
+24,694
+20,076% +$243K ﹤0.01% 4763
2022
Q1 		$1K Sell
123
-1,329
-92% -$13.1K ﹤0.01% 9930
2021
Q4 		$14K Buy
1,452
+1,446
+24,100% +$14.4K ﹤0.01% 8355
2021
Q3 		$0 Sell
6
-1,143
-99% -$11.2K ﹤0.01% 10084
2021
Q2 		$11K Buy
1,149
+1,132
+6,659% +$11.1K ﹤0.01% 7979
2021
Q1 		$0 Buy
+17
New +$172 ﹤0.01% 9465

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

UBS Group's TLSI Position: Q1 2026 in Review

UBS Group increased its TriSalus Life Sciences (TLSI) stake by 1,445% in Q1 2026, buying an estimated $364K and bringing the position to 79,552 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #6369.

UBS Group first reported a position in TLSI in Q1 2021 and has held it in 21 quarters since. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

  • UBS Group held 79,552 shares of TriSalus Life Sciences worth $318K as of Q1 2026.
  • UBS Group bought 74,403 TriSalus Life Sciences shares in Q1 2026, an estimated $364K.
  • TriSalus Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6369 holding.
  • UBS Group first reported a position in TriSalus Life Sciences in Q1 2021 and has held it in 21 quarters since.
  • 84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.